# Omeros Corp: financial statements, quarterly

OMER · Nasdaq · CIK 1285819 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/omer.md) · [Financials](/companies/omer/financials.md) · [Filings](/companies/omer/filings.md) · [Insiders](/companies/omer/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/omer/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001437749-26-016720.md) | [0.0](/filings/0001437749-26-027318.md) | not reported | not reported | [9.9](/filings/0001437749-26-016720.md) | [28.5](/filings/0001437749-26-027318.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001437749-26-016720.md) | [0.0](/filings/0001437749-26-027318.md) | not reported | not reported | [0.6](/filings/0001437749-26-016720.md) | [0.8](/filings/0001437749-26-027318.md) |
| Research and development | $m | [31.7](/filings/0001437749-24-034903.md) | [28.9 d](/filings/0001437749-26-010636.md) | [26.8](/filings/0001437749-25-017213.md) | [45.3](/filings/0001437749-25-026933.md) | [24.1](/filings/0001437749-25-034826.md) | [23.3 d](/filings/0001437749-26-010636.md) | [23.8](/filings/0001437749-26-016720.md) | [22.0](/filings/0001437749-26-027318.md) | [16.0](/filings/0001437749-25-034826.md) | [19.4 d](/filings/0001437749-26-010636.md) | [13.4](/filings/0001437749-26-016720.md) | [13.8](/filings/0001437749-26-027318.md) |
| Selling, general and administrative | $m | [16.4](/filings/0001437749-24-034903.md) | [10.9 d](/filings/0001437749-26-010636.md) | [12.3](/filings/0001437749-25-017213.md) | [13.8](/filings/0001437749-25-026933.md) | [11.3](/filings/0001437749-25-034826.md) | [10.0 d](/filings/0001437749-26-010636.md) | [11.1](/filings/0001437749-26-016720.md) | [10.3](/filings/0001437749-26-027318.md) | [10.4](/filings/0001437749-25-034826.md) | [9.6 d](/filings/0001437749-26-010636.md) | [13.4](/filings/0001437749-26-016720.md) | [13.9](/filings/0001437749-26-027318.md) |
| Operating income | $m | [(48.2)](/filings/0001437749-24-034903.md) | [(39.8) d](/filings/0001437749-26-010636.md) | [(39.0)](/filings/0001437749-25-017213.md) | [(59.2)](/filings/0001437749-25-026933.md) | [(35.4)](/filings/0001437749-25-034826.md) | [(33.4) d](/filings/0001437749-26-010636.md) | [(35.0)](/filings/0001437749-26-016720.md) | [(32.4)](/filings/0001437749-26-027318.md) | [(26.4)](/filings/0001437749-25-034826.md) | [(29.1) d](/filings/0001437749-26-010636.md) | [(17.4)](/filings/0001437749-26-016720.md) | [0.1](/filings/0001437749-26-027318.md) |
| Interest expense | $m | [7.9](/filings/0001437749-24-034903.md) | [7.1 d](/filings/0001437749-24-010416.md) | [8.2](/filings/0001437749-24-017047.md) | [9.2](/filings/0001437749-24-025181.md) | [4.1](/filings/0001437749-24-034903.md) | [3.2 d](/filings/0001437749-26-010636.md) | [3.7](/filings/0001437749-26-016720.md) | [0.0](/filings/0001437749-26-027318.md) | [(13.4)](/filings/0001437749-25-034826.md) | [8.7 d](/filings/0001437749-26-010636.md) | [5.9](/filings/0001437749-26-016720.md) | [7.6](/filings/0001437749-26-027318.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001437749-26-016720.md) | [0.0](/filings/0001437749-26-027318.md) | not reported | not reported | [0.1](/filings/0001437749-26-016720.md) | [0.0](/filings/0001437749-26-027318.md) |
| Net income | $m | [(37.8)](/filings/0001437749-24-034903.md) | [(9.1) d](/filings/0001437749-26-010636.md) | [(37.2)](/filings/0001437749-25-034826.md) | [(56.0)](/filings/0001437749-25-034826.md) | [(32.2)](/filings/0001437749-25-034826.md) | [(31.4) d](/filings/0001437749-26-010636.md) | [(33.5)](/filings/0001437749-26-027318.md) | [(25.4)](/filings/0001437749-26-027318.md) | [(30.9)](/filings/0001437749-25-034826.md) | [86.5 d](/filings/0001437749-26-010636.md) | [56.1](/filings/0001437749-26-027318.md) | [13.2](/filings/0001437749-26-027318.md) |
| Diluted EPS | $ per share | not reported | not reported | [(0.63)](/filings/0001437749-25-017213.md) | [(0.97)](/filings/0001437749-25-026933.md) | [(0.56)](/filings/0001437749-25-034826.md) | not reported | [(0.58)](/filings/0001437749-26-016720.md) | [(0.43)](/filings/0001437749-26-027318.md) | [(0.47)](/filings/0001437749-25-034826.md) | not reported | [0.62](/filings/0001437749-26-016720.md) | [0.15](/filings/0001437749-26-027318.md) |
| Basic EPS | $ per share | [(0.60)](/filings/0001437749-24-034903.md) | not reported | [(0.63)](/filings/0001437749-25-017213.md) | [(0.97)](/filings/0001437749-25-026933.md) | [(0.56)](/filings/0001437749-25-034826.md) | not reported | [(0.58)](/filings/0001437749-26-016720.md) | [(0.43)](/filings/0001437749-26-027318.md) | [(0.47)](/filings/0001437749-25-034826.md) | not reported | [0.78](/filings/0001437749-26-016720.md) | [0.18](/filings/0001437749-26-027318.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [30.6](/filings/0001437749-23-031250.md) | [7.1](/filings/0001437749-25-010216.md) | [1.8](/filings/0001437749-24-017047.md) | [2.1](/filings/0001437749-24-025181.md) | [1.5](/filings/0001437749-24-034903.md) | [3.4](/filings/0001437749-26-010636.md) | [4.3](/filings/0001437749-25-017213.md) | [1.9](/filings/0001437749-25-026933.md) | [2.4](/filings/0001437749-25-034826.md) | [9.7](/filings/0001437749-26-027318.md) | [1.9](/filings/0001437749-26-016720.md) | [2.0](/filings/0001437749-26-027318.md) |
| Current assets | $m | [351](/filings/0001437749-23-031250.md) | [218](/filings/0001437749-25-010216.md) | [281](/filings/0001437749-24-017047.md) | [203](/filings/0001437749-24-025181.md) | [165](/filings/0001437749-24-034903.md) | [134](/filings/0001437749-26-010636.md) | [96.2](/filings/0001437749-25-017213.md) | [69.6](/filings/0001437749-25-026933.md) | [71.8](/filings/0001437749-25-034826.md) | [216](/filings/0001437749-26-027318.md) | [180](/filings/0001437749-26-016720.md) | [185](/filings/0001437749-26-027318.md) |
| Total assets | $m | [493](/filings/0001437749-23-031250.md) | [378](/filings/0001437749-25-010216.md) | [437](/filings/0001437749-24-017047.md) | [356](/filings/0001437749-24-025181.md) | [313](/filings/0001437749-24-034903.md) | [277](/filings/0001437749-26-010636.md) | [235](/filings/0001437749-25-017213.md) | [201](/filings/0001437749-25-026933.md) | [186](/filings/0001437749-25-034826.md) | [326](/filings/0001437749-26-027318.md) | [286](/filings/0001437749-26-016720.md) | [287](/filings/0001437749-26-027318.md) |
| Current liabilities | $m | [147](/filings/0001437749-23-031250.md) | [53.3](/filings/0001437749-25-010216.md) | [59.1](/filings/0001437749-24-017047.md) | [59.5](/filings/0001437749-24-025181.md) | [55.6](/filings/0001437749-24-034903.md) | [79.5](/filings/0001437749-26-010636.md) | [83.2](/filings/0001437749-25-017213.md) | [85.5](/filings/0001437749-25-026933.md) | [80.8](/filings/0001437749-25-034826.md) | [78.1](/filings/0001437749-26-027318.md) | [59.4](/filings/0001437749-26-016720.md) | [95.0](/filings/0001437749-26-027318.md) |
| Long-term debt | $m | [317](/filings/0001437749-23-031250.md) | [213](/filings/0001437749-24-010416.md) | not reported | [165](/filings/0001437749-24-025181.md) | [165](/filings/0001437749-24-034903.md) | [165](/filings/0001437749-26-010636.md) | [165](/filings/0001437749-25-017213.md) | [155](/filings/0001437749-25-026933.md) | [155](/filings/0001437749-25-034826.md) | [87.9](/filings/0001437749-26-010636.md) | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(14.0)](/filings/0001437749-24-034903.md) | [(25.0)](/filings/0001437749-26-010636.md) | [(71.3)](/filings/0001437749-25-034826.md) | [(125)](/filings/0001437749-25-034826.md) | [(154)](/filings/0001437749-25-034826.md) | [(183)](/filings/0001437749-26-027318.md) | [(214)](/filings/0001437749-26-027318.md) | [(229)](/filings/0001437749-26-027318.md) | [(220)](/filings/0001437749-25-034826.md) | [(121)](/filings/0001437749-26-027318.md) | [(63.3)](/filings/0001437749-26-027318.md) | [(51.3)](/filings/0001437749-26-027318.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(32.6) d](/filings/0001437749-24-034903.md) | [(34.8) d](/filings/0001437749-26-010636.md) | [(41.8)](/filings/0001437749-25-017213.md) | [(46.0) d](/filings/0001437749-25-026933.md) | [(32.1) d](/filings/0001437749-25-034826.md) | [(29.0) d](/filings/0001437749-26-010636.md) | [(35.8)](/filings/0001437749-26-016720.md) | [(21.9) d](/filings/0001437749-26-027318.md) | [(18.5) d](/filings/0001437749-25-034826.md) | [(39.8) d](/filings/0001437749-26-010636.md) | [(14.5)](/filings/0001437749-26-016720.md) | [4.1 d](/filings/0001437749-26-027318.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001437749-24-034903.md) | [0.1 d](/filings/0001437749-26-010636.md) | [0.1](/filings/0001437749-25-017213.md) | [0.1 d](/filings/0001437749-25-026933.md) | [0.0 d](/filings/0001437749-25-034826.md) | [0.0 d](/filings/0001437749-26-010636.md) | [0.0](/filings/0001437749-26-016720.md) | [0.0 d](/filings/0001437749-26-027318.md) | [0.0 d](/filings/0001437749-25-034826.md) | [0.0 d](/filings/0001437749-26-010636.md) | [0.0](/filings/0001437749-26-016720.md) | [0.0 d](/filings/0001437749-26-027318.md) |
| Share repurchases | $m | [0.0 d](/filings/0001437749-24-034903.md) | [4.7 d](/filings/0001437749-26-010636.md) | [11.9](/filings/0001437749-25-017213.md) | [0.0 d](/filings/0001437749-25-026933.md) | [0.0 d](/filings/0001437749-25-034826.md) | [0.0 d](/filings/0001437749-26-010636.md) | [0.0](/filings/0001437749-26-016720.md) | [0.0 d](/filings/0001437749-26-027318.md) | [0.0 d](/filings/0001437749-25-034826.md) | [0.0 d](/filings/0001437749-26-010636.md) | [4.2](/filings/0001437749-26-016720.md) | [5.7 d](/filings/0001437749-26-027318.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [61.9](/filings/0001558370-22-008120.md) | [62.4](/filings/0001558370-22-012884.md) | [62.5](/filings/0001558370-22-017153.md) | [62.7](/filings/0001558370-23-008814.md) | [62.7](/filings/0001558370-23-014095.md) | [62.7](/filings/0001558370-22-017153.md) | [62.8](/filings/0001558370-23-008814.md) | [62.8](/filings/0001558370-23-014095.md) | [58.1](/filings/0001437749-26-016720.md) | [58.6](/filings/0001437749-26-027318.md) | [90.1](/filings/0001437749-26-016720.md) | [89.6](/filings/0001437749-26-027318.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 72,388,316 at 2026-08-07, from the cover of the [10-Q filed 2026-08-12](/filings/0001437749-26-027318.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.